Thursday, March 12, 2020

Motion Preservation Devices Market Trends Estimates High Demand by 2022

The motion preservation devices market was valued at $920 million in 2015, and is projected to reach $1,902 million by 2022, registering a CAGR of 10.9% from 2016 to 2022, According to a new report published by Allied Market Research

Motion preservation devices are used to treat disorders associated with the spine. These devices are used to restore and maintain the normal alignment of the spine. The advent of minimally invasive spine surgery techniques and rise in incidence of spinal disorders drive the market. In addition, rise in geriatric population and technological developments in bone grafting products are anticipated to boost the demand for motion preservation devices, globally. However, unfavorable reimbursement scenario and stringent regulatory approval process hamper the market growth.


Artificial disc replacement segment generated the highest revenue in the global non-fusion/motion preservation devices market in 2015, owing to their increased preference over spinal fusion procedures. In addition, the nuclear disc prostheses segment is anticipated to grow rapidly, registering a CAGR of 11.1% during the forecast period.
The global motion preservation devices market is segmented on the basis of surgery into open spine surgery and minimally invasive spine surgery (MISS). The open spine surgery segment generated the highest revenue in 2015. However, the MISS segment is expected to grow at the highest CAGR during the study period.

North America accounted for the majority of revenue in 2015, and is expected to maintain its dominance throughout the forecast period. This is attributed to increased adoption of motion preservation devices in surgery and rise in incidence of spinal disorders and impairments, such as spinal stenosis. However, the Asia-Pacific region is projected to grow rapidly during the forecast period, registering a CAGR of 11.5%. Improving healthcare infrastructures and increase in expenditures in the emerging markets, such as India and China, to cater to the unmet medical needs in these countries have bolstered the market growth.

The key players in the motion preservation devices market have focused on expanding their business operations in the fast-growing emerging countries by adopting the new product launch strategy.

The major companies profiled Are:
  • Aurora Spine Corporation
  • B. Braun Melsungen AG
  • Depuy Synthes (Johnson & Johnson)
  • Globus Medical, Inc.
  • HPI Implants
  • Paradigm Spine
  • RTI Surgical, Inc.
  • Raymedica, Inc.
  • Spinal Kinetics, Inc.
  • Ulrich GmbH & Co. KG
  • Zimmer Biomet Holdings, Inc.

Key findings of Motion Preservation Market:
  • The artificial disc replacement devices segment accounted for nearly half of the global motion preservation devices market in 2015.
  • The nuclear disc prosthesis device segment is the fastest growing segment and is poised to grow at a CAGR of 11.1% during the forecast period.
  • The dynamic stabilization devices segment is expected to grow at a significant CAGR of 10.9%, owing to the use of flexible materials during dynamic stabilization procedure for restoring mobility in the spine.
  • France and Germany jointly accounted for more than one-third share of the global motion preservation devices market in 2015.
  • Japan was the major shareholder in the Asia-Pacific motion preservation devices market, accounting for more than one-third share in 2015.
Similar Report:





About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Market Pulse: https://blog.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

Tuesday, March 3, 2020

Liquid Biopsy Market Growth Prospect and Future Scenario by Key Players 2023

The global liquid biopsy market accounted for $634 million in 2016, and is estimated to reach at $3,805 million by 2023, registering a CAGR of 28.9% from 2017 to 2023. North America was the highest contributor in the liquid biopsy market in 2016; however, Asia-Pacific is anticipated to witness a highest growth rate throughout the forecast period.

Liquid biopsy tests prove to be an easy and non-invasive method to access to molecular information about the tumor genome. Moreover, these tests facilitate early detection of cancer recurrence and characterization of tumor dynamics. Safety and efficiency of cancer treatment is improved by the use of these tests, owing to their ability to characterize new lesions, implement apt therapeutic targets, and predict the treatment outcome.


The advantages of implementing liquid biopsy over conventional methods of solid tissue biopsy are expected to boost the growth of the market. The advantages of liquid biopsies, such as minimally invasiveness and metastatic relapse evaluation, are expected to increase the demand for these tests. Furthermore, the increase in disposable income among cancer patients, surge in prevalence of cancer cases, and patient preference for minimally invasive therapies are anticipated to fuel the market growth. Rise in healthcare expenditure in the developing countries, such as India and China, and use of liquid biopsy tests to treat rare cancers are expected to present multiple opportunities for market growth. However, this growth is restricted, owing to alternatives to liquid biopsies and unclear reimbursement & regulation scenario.

Reagent was the highest revenue contributor in 2016, and is anticipated to continue this trend in the future. The requirement of reagents to execute liquid biopsy tests and their applicability are expected to boost the growth of this segment.

Lung cancer dominates the cancer by type segment of liquid biopsy market. The U.S. Food and Drug Administration (FDA) has also approved a liquid biopsy companion diagnostic test called cobas EGFR mutation test v2 to identify patients with metastatic non-small cell lung cancer (NSCLC) In addition, the growth in prevalence of lung cancer has contributed to provide lucrative opportunities in the market.

In 2016, North America accounted for highest contribution to the total revenue generated, owing to the high prevalence rate of cancer and high adoption rate of novel liquid biopsy tests. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, attributable to rise in disposable income, increase in government initiatives to modernize healthcare infrastructure, and rise in healthcare expenditure.

The Major key companies profiled Are:
  • Biocept, Inc.
  • Qiagen
  • F. Hoffmann-La Roche AG
  • Bio-Rad Laboratories Inc.
  • Myriad Genetics
  • Janssen Diagnostics, LLC.
  • Trovagene Inc.
  • Guardant Health Inc.
  • GRAIL
  • MDX Health SA.

Key Findings of the Liquid Biopsy Market:
  • The government & academic research center segment is projected to grow at the highest rate during the analysis period.
  • Hospital & laboratory segment was the highest revenue-generating segment, and is expected to continue its dominance in future.
  • North America dominated global liquid biopsy market, and is projected to grow at a CAGR of 28.1%.
  • China is expected to grow at the highest CAGR of 34.1% in Asia-Pacific region.
  • The instruments segment is anticipated to grow at the highest CAGR of 29.8% during the forecast period.
Similar Reports:





About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Market Pulse: https://blog.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research